UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 1, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At November 6, 2017, 5,960,707,317 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended October 1, 2017 and October 2, 2016

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended October 1, 2017 and October 2, 2016

Condensed Consolidated Balance Sheets as of October 1, 2017 and December 31, 2016

Condensed Consolidated Statements of Cash Flows for the nine months ended October 1, 2017 and October 2, 2016

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

45

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

46

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

106

Item 4.

Controls and Procedures

106

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

107

Item 1A.

Risk Factors

107

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

109

Item 3.

Defaults Upon Senior Securities

109

Item 4.

Mine Safety Disclosures

109

Item 5.

Other Information

109

Item 6.

Exhibits

110

Signature

111

GLOSSARY OF DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:

2016 Financial Report

Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016

2016 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2016

AAV

Adeno-Associated Virus

ACA (Also referred to as U.S. Healthcare Legislation)

U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act

ACIP

Advisory Committee on Immunization Practices

ALK

anaplastic lymphoma kinase

Allergan

Allergan plc

Alliance revenues

Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

Anacor

Anacor Pharmaceuticals, Inc.

Astellas

Astellas Pharma U.S., Inc.

ASU

Accounting Standards Update

ATM-AVI

aztreonam-avibactam

Avillion

Avillion LLP

Bamboo

Bamboo Therapeutics, Inc.

BMS

Bristol-Myers Squibb Company

CDC

U.S. Centers for Disease Control and Prevention

Cellectis

Cellectis SA

Citibank

Citibank N.A.

cGMPs

current Good Manufacturing Practices

Developed Markets

U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand

EEA

European Economic Area

EH

Essential Health

EMA

European Medicines Agency

Emerging Markets

Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey

EPS

earnings per share

EU

European Union

EURIBOR

Euro Interbank Offered Rate

Exchange Act

Securities Exchange Act of 1934, as amended

FASB

Financial Accounting Standards Board

FDA

U.S. Food and Drug Administration

GAAP

Generally Accepted Accounting Principles

GIST

gastrointestinal stromal tumors

GPD

Global Product Development

HER2-

human epidermal growth factor receptor 2-negative

HIS

Hospira Infusion Systems

Hisun

Zhejiang Hisun Pharmaceuticals Co., Ltd.

Hisun Pfizer

Hisun Pfizer Pharmaceuticals Company Limited

Hospira

Hospira, Inc.

HR+

hormone receptor-positive

ICU Medical

ICU Medical, Inc.

IH

Innovative Health

InnoPharma

InnoPharma, Inc.

IPR&D

in-process research and development

IRS

U.S. Internal Revenue Service

IV

intravenous

Janssen

Janssen Biotech Inc.

King

King Pharmaceuticals, Inc.

LDL

low density lipoprotein

LEP

Legacy Established Products

LIBOR

London Interbank Offered Rate

Lilly

Eli Lilly & Company

LOE

loss of exclusivity

MCO

Managed Care Organization

MD&A

Management s Discussion and Analysis of Financial Condition and Results of Operations

Medivation

Medivation, Inc.

Merck

Merck & Co., Inc.

Meridian

Meridian Medical Technologies, Inc.

Moody s

Moody s Investors Service

NDA

new drug application

NovaQuest

NovaQuest Co-Investment Fund V, L.P.

NSCLC

non-small cell lung cancer

NYSE

New York Stock Exchange

OPKO

OPKO Health, Inc.

OTC

over-the-counter

PBM

Pharmacy Benefit Manager

Pharmacia

Pharmacia Corporation

PP&E

Property, plant & equipment

Quarterly Report on Form 10-Q

Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2017

RCC

renal cell carcinoma

R&D

research and development

RPI

RPI Finance Trust

Sandoz

Sandoz, Inc., a division of Novartis AG

Sangamo

Sangamo Therapeutics, Inc.

SEC

U.S. Securities and Exchange Commission

SFJ

SFJ Pharmaceuticals Group

SIP

Sterile Injectable Pharmaceuticals

S&P

Standard and Poor s

Teuto

Laborat rio Teuto Brasileiro S.A.

U.K.

United Kingdom

U.S.

United States

ViiV

ViiV Healthcare Limited

WRD

Worldwide Research and Development

Zoetis

Zoetis Inc.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

October 1,

2017

October 2,

2016

October 1,

2017

October 2,

2016

Revenues

13,168

13,045

38,843

39,196

Costs and expenses:

Cost of sales(a)

2,847

3,085

7,980

9,111

Selling, informational and administrative expenses(a)

3,500

3,559

10,233

10,414

Research and development expenses(a)

1,859

1,881

5,346

5,360

Amortization of intangible assets

1,177

968

3,571

2,934

Restructuring charges and certain acquisition-related costs

149

531

377

988

Other (income)/deductions net

51

1,417

(16

2,815

Income from continuing operations before provision for taxes on income

3,585

1,604

11,351

7,575

Provision for taxes on income(b)

727

249

2,287

1,109

Income from continuing operations(b)

2,858

1,355

9,064

6,465

Discontinued operations net of tax

Net income before allocation to noncontrolling interests(b)

2,858

1,355

9,066

6,465

Less: Net income attributable to noncontrolling interests

18

32

25

Net income attributable to Pfizer Inc.(b)

2,840

1,355

9,034

6,440

Earnings per common share basic(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.48

0.22

1.51

1.06

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.48

0.22

1.51

1.06

Earnings per common share diluted(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.47

0.22

1.49

1.04

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.47

0.22

1.49

1.04

Weighted-average shares basic

5,951

6,066

5,972

6,095

Weighted-average shares diluted(b)

6,041

6,150

6,057

6,175

Cash dividends paid per common share

0.32

0.30

0.96

0.90

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

(b)

Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies Adoption of New Accounting Standards.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

October 1,

2017

October 2,

2016

October 1,

2017

October 2,

2016

Net income before allocation to noncontrolling interests

2,858

1,355

9,066

6,465

Foreign currency translation adjustments, net

878

417

1,352

998

Reclassification adjustments(a)

(3

110

875

417

1,461

998

Unrealized holding losses on derivative financial instruments, net

(50

(126

(149

(970

Reclassification adjustments for realized (gains)/losses(b)

56

150

(393

280

24

(542

(690

Unrealized holding gains on available-for-sale securities, net

384

261

698

740

Reclassification adjustments for realized gains(b)

(278

(112

(181

(129

106

149

518

611

Benefit plans: actuarial losses, net

(103

(82

(41

(101

Reclassification adjustments related to amortization(c)

140

140

448

418

Reclassification adjustments related to settlements, net(c)

38

28

89

76

Other

(76

69

(111

51

(1

155

384

444

Benefit plans: prior service (costs)/credits and other, net

95

(2

182

Reclassification adjustments related to amortization(c)

(46

(45

(138

(127

Reclassification adjustments related to curtailments, net(c)

(3

(8

(14

(14

Other

12

(48

48

(151

54

Other comprehensive income, before tax

938

793

1,669

1,417

Tax provision/(benefit) on other comprehensive income(d)

(80

116

(218

111

Other comprehensive income before allocation to noncontrolling interests

1,018

677

1,888

1,306

Comprehensive income before allocation to noncontrolling interests

3,876

2,031

10,953

7,771

Less: Comprehensive income attributable to noncontrolling interests

19

48

24

Comprehensive income attributable to Pfizer Inc.

3,857

2,032

10,906

7,747

(a)

The foreign currency translation adjustments reclassified into Other (income)/deductions net in the condensed consolidated statements of income primarily result from sale of our 40% ownership investment in Teuto. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.

(b)

Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.

(c)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(d)

See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

October 1,

2017

December 31,

2016

(Unaudited)

Assets

Cash and cash equivalents

2,779

2,595

Short-term investments

14,146

15,255

Trade accounts receivable, less allowance for doubtful accounts: 2017 $590; 2016 $609

10,002

8,225

Inventories

7,925

6,783

Current tax assets

3,263

3,041

Other current assets

2,158

2,249

Assets held for sale

16

801

Total current assets

40,291

38,949

Long-term investments

7,311

7,116

Property, plant and equipment, less accumulated depreciation: 2017 $15,906; 2016 $14,807

13,505

13,318

Identifiable intangible assets, less accumulated amortization

49,721

52,648

Goodwill

56,078

54,449

Noncurrent deferred tax assets and other noncurrent tax assets

1,858

1,812

Other noncurrent assets

3,388

3,323

Total assets

172,151

171,615

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2017 $3,072; 2016 $4,225

9,448

10,688

Trade accounts payable

3,480

4,536

Dividends payable

1,909

1,944

Income taxes payable

1,003

437

Accrued compensation and related items

1,932

2,487

Other current liabilities

10,446

11,023

Total current liabilities

28,217

31,115

Long-term debt

34,503

31,398

Pension benefit obligations, net

5,531

6,406

Postretirement benefit obligations, net

1,687

1,766

Noncurrent deferred tax liabilities

30,411

30,753

Other taxes payable

4,304

4,000

Other noncurrent liabilities

6,388

6,337

Total liabilities

111,041

111,776

Commitments and Contingencies

Preferred stock

22

24

Common stock

463

461

Additional paid-in capital

83,827

82,685

Treasury stock

(89,421

(84,364

Retained earnings

75,043

71,774

Accumulated other comprehensive loss

(9,164

(11,036

Total Pfizer Inc. shareholders equity

60,770

59,544

Equity attributable to noncontrolling interests

340

296

Total equity

61,110

59,840

Total liabilities and equity

172,151

171,615

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS OF DOLLARS)

October 1,

2017

October 2,

2016

Operating Activities

Net income before allocation to noncontrolling interests(a)

9,066

6,465

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

4,695

4,208

Asset write-offs and impairments

326

1,146

Loss on sale of HIS net assets

52

1,422

Deferred taxes from continuing operations

241

(1,335

Share-based compensation expense

595

532

Benefit plan contributions in excess of expense

(1,042

(775

Other adjustments, net

(561

68

Other changes in assets and liabilities, net of acquisitions and divestitures(a)

(3,644

(1,582

Net cash provided by operating activities(a)

9,728

10,151

Investing Activities

Purchases of property, plant and equipment

(1,256

(1,134

Purchases of short-term investments

(6,469

(15,170

Proceeds from redemptions/sales of short-term investments

5,783

20,685

Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less

2,758

6,485

Purchases of long-term investments

(2,526

(4,771

Proceeds from redemptions/sales of long-term investments

2,417

6,915

Acquisitions of businesses, net of cash acquired

(1,000

(17,679

Acquisitions of intangible assets

(188

(96

Other investing activities, net

519

60

Net cash provided by/(used in) investing activities

38

(4,704

Financing Activities

Proceeds from short-term borrowings

7,003

6,397

Principal payments on short-term borrowings

(7,691

(3,321

Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less

555

(963

Proceeds from issuance of long-term debt

5,273

5,031

Principal payments on long-term debt

(4,474

(4,317

Purchases of common stock

(5,000

(5,000

Cash dividends paid

(5,750

(5,496

Proceeds from exercise of stock options

656

946

Other financing activities, net(a)

(223

(192

Net cash used in financing activities(a)

(9,650

(6,915

Effect of exchange-rate changes on cash and cash equivalents

67

(79

Net increase/(decrease) in cash and cash equivalents

184

(1,547

Cash and cash equivalents, beginning

2,595

3,641

Cash and cash equivalents, end

2,779

2,094

Supplemental Cash Flow Information

Non-cash transactions:

Receipt of ICU Medical common stock(b)

428

Promissory note from ICU Medical(b)

75

Cash paid (received) during the period for:

Income taxes

1,424

1,430

Interest

1,101

1,177

Interest rate hedges

(183

(356

(a)

Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.

(b)

In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million. For additional information, see Note 2B. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments: Sale of Hospira Infusion Systems Net Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.

We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.

The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2017 and August 28, 2016. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2017 and October 2, 2016.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016 Form 10-K.

We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2016 Financial Report.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

Our recent significant business development activities include:

On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the third quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH s operating results, for the third quarter of 2016 reflect three months of HIS global operations. Our financial results, and EH s operating results, for the first nine months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first nine months of 2016 reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities.

On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH s operating results, and cash flows for the third quarter and first nine months of 2017 reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca.

On September 28, 2016, we acquired Medivation for $81.50 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH s operating results, and cash flows for the third quarter and first nine months of 2017. In accordance with our domestic and international reporting periods, our consolidated financial statements for the third quarter and first nine months of 2016 reflect three business days of Medivation operations, which were immaterial.